Chacko Jacob 4
4 · Oric Pharmaceuticals, Inc. · Filed Oct 2, 2025
Insider Transaction Report
Form 4
Chacko Jacob
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2025-09-30$12.01/sh−34,538$414,750→ 621,881 total - Sale
Common Stock
2025-10-01$12.05/sh−53,001$638,805→ 568,880 total
Footnotes (4)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.
- [F2]Represents the weighted average share price of an aggregate total of 34,538 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.
- [F4]Represents the weighted average share price of an aggregate total of 53,001 shares sold in the price range of $12.00 to $12.13 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.